Historical Stock Chart
3 Months : From Nov 2019 to Feb 2020
By Maria Armental
Novartis AG said its cancer drug Kymriah showed consistent efficacy and safety outcomes when used in real-world settings on a broader group of U.S. patients.
The analyses are from a readout of a 15-year post-marketing study looking at Kymriah in adults with relapsed or refractory diffuse large B cell lymphoma, the most common type of lymphoma, and in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia.
Kymriah (tisagenlecleucel), which company officials expect to reach blockbuster potential over the next five years, is part of a type of therapies known as Car-T that use genetically engineered T-cells to attack the blood cancer.
Write to Maria Armental at firstname.lastname@example.org
(END) Dow Jones Newswires
December 09, 2019 16:15 ET (21:15 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.